Oxford GlycoSciences submits Vevesca NDA
This article was originally published in Pharmaceutical Approvals Monthly
Oxford GlycoSciences completes its rolling NDA submission for the type I Gaucher disease therapy Vevesca (OGT 918) Aug. 21. The submission for the oral glycolipid storage disorders agent, initiated in March, includes data on use of the drug as monotherapy as well as in combination with Genzyme's Cerezyme (imiglucerase). Results of an extension study with Vevesca monotherapy will be presented Sept. 22 at the European Society of Glycolipid Disorders workshop in the Netherlands
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.